"Uracil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of four nucleotide bases in the nucleic acid RNA.
| Descriptor ID |
D014498
|
| MeSH Number(s) |
D03.383.742.698.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Uracil".
Below are MeSH descriptors whose meaning is more specific than "Uracil".
This graph shows the total number of publications written about "Uracil" by people in this website by year, and whether "Uracil" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 9 | 11 | 20 |
| 2018 | 4 | 12 | 16 |
| 2019 | 1 | 4 | 5 |
| 2020 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Uracil" by people in Profiles.
-
Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease. ChemMedChem. 2021 05 06; 16(9):1425-1426.
-
Evidence for Strong Mutation Bias toward, and Selection against, U Content in SARS-CoV-2: Implications for Vaccine Design. Mol Biol Evol. 2021 01 04; 38(1):67-83.
-
A Path toward SARS-CoV-2 Attenuation: Metabolic Pressure on CTP Synthesis Rules the Virus Evolution. Genome Biol Evol. 2020 12 06; 12(12):2467-2485.
-
Point mutation bias in SARS-CoV-2 variants results in increased ability to stimulate inflammatory responses. Sci Rep. 2020 10 20; 10(1):17766.
-
Mutation Patterns of Human SARS-CoV-2 and Bat RaTG13 Coronavirus Genomes Are Strongly Biased Towards C>U Transitions, Indicating Rapid Evolution in Their Hosts. Genes (Basel). 2020 07 07; 11(7).
-
Rampant C?U Hypermutation in the Genomes of SARS-CoV-2 and Other Coronaviruses: Causes and Consequences for Their Short- and Long-Term Evolutionary Trajectories. mSphere. 2020 06 24; 5(3).
-
Elucidating cylindrospermopsin toxicity via synthetic analogues: An in vitro approach. Chemosphere. 2019 Nov; 234:139-147.
-
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. Hepatology. 2019 09; 70(3):771-787.
-
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol. 2019 09; 71(3):473-485.
-
Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences. Eur J Gastroenterol Hepatol. 2019 04; 31(4):534-539.